IGM Biosciences Statistics
Total Valuation
IGM Biosciences has a market cap or net worth of $72.93 million. The enterprise value is -$65.68 million.
Important Dates
The next estimated earnings date is Wednesday, May 7, 2025, after market close.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
IGM Biosciences has 59.78 million shares outstanding. The number of shares has increased by 15.68% in one year.
| Current Share Class | 34.39M |
| Shares Outstanding | 59.78M |
| Shares Change (YoY) | +15.68% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 2.45% |
| Owned by Institutions (%) | 11.09% |
| Float | 10.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 27.56 |
| Forward PS | 5.54 |
| PB Ratio | 1.51 |
| P/TBV Ratio | 1.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.14, with a Debt / Equity ratio of 0.94.
| Current Ratio | 5.14 |
| Quick Ratio | 4.90 |
| Debt / Equity | 0.94 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -155.76% and return on invested capital (ROIC) is -72.02%.
| Return on Equity (ROE) | -155.76% |
| Return on Assets (ROA) | -35.23% |
| Return on Invested Capital (ROIC) | -72.02% |
| Return on Capital Employed (ROCE) | -85.16% |
| Revenue Per Employee | $17,980 |
| Profits Per Employee | -$1.31M |
| Employee Count | 149 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.58% in the last 52 weeks. The beta is 0.57, so IGM Biosciences's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | -86.58% |
| 50-Day Moving Average | 1.28 |
| 200-Day Moving Average | 7.91 |
| Relative Strength Index (RSI) | 47.67 |
| Average Volume (20 Days) | 167,591 |
Short Selling Information
The latest short interest is 980,300, so 1.64% of the outstanding shares have been sold short.
| Short Interest | 980,300 |
| Short Previous Month | 928,250 |
| Short % of Shares Out | 1.64% |
| Short % of Float | 9.18% |
| Short Ratio (days to cover) | 4.91 |
Income Statement
In the last 12 months, IGM Biosciences had revenue of $2.68 million and -$195.80 million in losses. Loss per share was -$3.24.
| Revenue | 2.68M |
| Gross Profit | -152.51M |
| Operating Income | -194.22M |
| Pretax Income | -236.33M |
| Net Income | -195.80M |
| EBITDA | -185.11M |
| EBIT | -194.22M |
| Loss Per Share | -$3.24 |
Full Income StatementBalance Sheet
The company has $183.79 million in cash and $45.19 million in debt, giving a net cash position of $138.60 million or $2.32 per share.
| Cash & Cash Equivalents | 183.79M |
| Total Debt | 45.19M |
| Net Cash | 138.60M |
| Net Cash Per Share | $2.32 |
| Equity (Book Value) | 48.17M |
| Book Value Per Share | 0.81 |
| Working Capital | 155.98M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$153.00 million and capital expenditures -$5.85 million, giving a free cash flow of -$158.85 million.
| Operating Cash Flow | -153.00M |
| Capital Expenditures | -5.85M |
| Free Cash Flow | -158.85M |
| FCF Per Share | -$2.66 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -7,249.61% |
| Pretax Margin | -7,308.51% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IGM Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.68% |
| Shareholder Yield | n/a |
| Earnings Yield | -268.48% |
| FCF Yield | -217.82% |
Analyst Forecast
The average price target for IGM Biosciences is $6.14, which is 397.17% higher than the current price. The consensus rating is "Hold".
| Price Target | $6.14 |
| Price Target Difference | 397.17% |
| Analyst Consensus | Hold |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 33.50% |
| EPS Growth Forecast (5Y) | -23.89% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
IGM Biosciences has an Altman Z-Score of -5.31 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.31 |
| Piotroski F-Score | 3 |